NCT04443192 - A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiXZ Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 3, 2020

Primary Completion Date

September 12, 2022

Study Completion Date

September 12, 2022

Conditions

Alpha1 Anti-Trypsin Deficiency

Interventions

DRUG

ZF874

ZF874 is a novel chemical chaperone that is specifically designed to rescue the folding of the Z variant of alpha-1-antitrypsin (A1AT). It is being developed for the treatment of alpha-1-antitrypsin deficiency (AATD) caused by the Z-mutation.

DRUG

Placebo

Placebo to ZF874

Trial Locations (5)

M13 9NQ

MAC Clinical Research Manchester, Manchester

S75 3DL

MAC Clinical Research, Barnsley, Barnsley

LS10 1DU

MAC Clinical Research, Leeds, Leeds

NW10 7EW

Hammersmith Medicines Research, London

TS17 6EW

MAC Clinical Research, Teesside, Stockton-on-Tees